131 related articles for article (PubMed ID: 19690506)
1. Population-based BRCA1/BRCA2 screening in Ashkenazi Jews: a call for evidence.
Levy-Lahad E
Genet Med; 2009 Sep; 11(9):620-1. PubMed ID: 19690506
[No Abstract] [Full Text] [Related]
2. Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time.
Lynce F; Isaacs C
J Natl Compr Canc Netw; 2016 Jun; 14(6):809-12. PubMed ID: 27283172
[No Abstract] [Full Text] [Related]
3. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
4. Precision medicine meets public health: population screening for BRCA1 and BRCA2.
Levy-Lahad E; Lahad A; King MC
J Natl Cancer Inst; 2015 Jan; 107(1):420. PubMed ID: 25550384
[No Abstract] [Full Text] [Related]
5. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
[TBL] [Abstract][Full Text] [Related]
6. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
[TBL] [Abstract][Full Text] [Related]
7. Unknown significance.
Couzin-Frankel J
Science; 2014 Dec; 346(6214):1167-70. PubMed ID: 25477439
[No Abstract] [Full Text] [Related]
8. [BRCAmutations more frequent in people of Jewish ancestry].
Menko FH; Rosenberg EH; van der Kolk LE
Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30875152
[TBL] [Abstract][Full Text] [Related]
9. Two BRCA1/2 founder mutations in Jews of Sephardic origin.
Sagi M; Eilat A; Ben Avi L; Goldberg Y; Bercovich D; Hamburger T; Peretz T; Lerer I
Fam Cancer; 2011 Mar; 10(1):59-63. PubMed ID: 21063910
[TBL] [Abstract][Full Text] [Related]
10. Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.
Chodick G; Struewing JP; Ron E; Rutter JL; Iscovich J
Eur J Med Genet; 2008; 51(2):141-7. PubMed ID: 18158280
[TBL] [Abstract][Full Text] [Related]
11. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
12. Familial communication and cascade testing among relatives of BRCA population screening participants.
Lieberman S; Lahad A; Tomer A; Koka S; BenUziyahu M; Raz A; Levy-Lahad E
Genet Med; 2018 Nov; 20(11):1446-1454. PubMed ID: 29595811
[TBL] [Abstract][Full Text] [Related]
13. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
[TBL] [Abstract][Full Text] [Related]
14. The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
Barnes-Kedar I; Bernstein-Molho R; Ginzach N; Hartmajer S; Shapira T; Magal N; Kalis ML; Peretz T; Shohat M; Basel-Salmon L; Friedman E; Bazak L; Goldberg Y
Breast Cancer Res Treat; 2018 Nov; 172(1):151-157. PubMed ID: 30014164
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue.
Rubinstein WS; Jiang H; Dellefave L; Rademaker AW
Genet Med; 2009 Sep; 11(9):629-39. PubMed ID: 19606050
[TBL] [Abstract][Full Text] [Related]
16. Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women.
Distelman-Menachem T; Shapira T; Laitman Y; Kaufman B; Barak F; Tavtigian S; Friedman E
Fam Cancer; 2009; 8(2):127-33. PubMed ID: 18798010
[TBL] [Abstract][Full Text] [Related]
17. Community attitudes towards a Jewish community BRCA1/2 testing program.
Cousens N; Kaur R; Meiser B; Andrews L
Fam Cancer; 2017 Jan; 16(1):17-28. PubMed ID: 27480161
[TBL] [Abstract][Full Text] [Related]
18. Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities.
Augustyn AM; Agostino NM; Namey TL; Nair S; Martino MA
Breast Cancer Res Treat; 2011 Sep; 129(2):629-34. PubMed ID: 21607582
[TBL] [Abstract][Full Text] [Related]
19. Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.
D'Andrea E; Marzuillo C; De Vito C; Di Marco M; Pitini E; Vacchio MR; Villari P
Genet Med; 2016 Dec; 18(12):1171-1180. PubMed ID: 27906166
[TBL] [Abstract][Full Text] [Related]
20. Population Screening for Inherited Predisposition to Breast and Ovarian Cancer.
Manchanda R; Lieberman S; Gaba F; Lahad A; Levy-Lahad E
Annu Rev Genomics Hum Genet; 2020 Aug; 21():373-412. PubMed ID: 32315550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]